Single-Dose Baloxavir Treatment Can Reduce Influenza Transmission

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 24, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, April 24, 2025 -- A single-dose baloxavir treatment can reduce influenza transmission from index patients to household contacts, according to a study published in the April 24 issue of the New England Journal of Medicine.

Arnold S. Monto, M.D., from the University of Michigan School of Public Health in Ann Arbor, and colleagues examined the efficacy of single-dose baloxavir treatment to reduce influenza transmission from index patients to household contacts in a multicountry, phase 3b trial. Influenza-positive index patients aged 5 to 64 years were randomly assigned to receive baloxavir or placebo within 48 hours after symptom onset (726 and 731 patients, respectively).

The researchers found that transmission of laboratory-confirmed influenza was significantly lower with baloxavir than placebo by day 5 (adjusted incidence, 9.5 versus 13.4 percent; adjusted odds ratio, 0.68; 95.38 percent confidence interval, 0.50 to 0.93; P = 0.01), with an adjusted relative risk reduction of 29 percent. By day 5, the adjusted incidence of transmission of influenza virus that resulted in symptoms was 5.8 and 7.6 percent with baloxavir and placebo, respectively, but the difference was not significant (adjusted odds ratio, 0.75; 95.38 percent confidence interval, 0.50 to 1.12; P = 0.16). During the follow-up period, emergence of drug-resistant viruses occurred in 7.2 percent of index patients in the baloxavir group; there were no resistant viruses detected in household contacts. There were no new safety signals reported.

"Although vaccines will remain the primary control measure for influenza epidemics and pandemics, antiviral drugs play a complementary role, particularly in a pandemic scenario, as well as in persons who are not vaccinated seasonally," the authors write.

Several authors disclosed ties to F. Hoffmann-La Roche, which manufactures baloxavir and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords